National

Pro Rata

Axios Pro Rata

Boston Scientific (NYSE: BSX) is considering a sale process for its snake venom unit, which could fetch upwards of $1 billion, per multiple reports.

Why it matters: Because snake antivenom products, like Boston Scientific's CroFab, are the sort of niche things you never think about until that unfortunate moment when it's all you can think about.

The bottom line: "Boston Scientific acquired the business in its $4.2 billion takeover of BTG PLC last year. The company is retaining the other parts of BTG’s portfolio, including liver and kidney cancer treatments." — Bloomberg

Boston Scientific considering sale of snake venom unit

Business

Boston Scientific

Boston Scientific (NYSE: BSX) is considering a sale process for its snake venom unit, which could fetch upwards of $1 billion, per multiple reports.Why it matters: Because snake antivenom products, like Boston Scientific&#x27;s CroFab, are the sort of niche things you never think about until that unfortunate moment when it&#x27;s all you can think about.

After a record economic expansion, the coronavirus pandemic sent the U.S. economy into a recession as unemployment soared to staggering heights. The country now faces urgent questions about how much stimulus is needed for reeling consumers and businesses, and what a recovery might look like.

Economy & Business

A look at the scientific breakthroughs changing the world, explorations in space and in worlds beyond our own and the threats posed to us by our own planet, both out of our control and of our own making.

Boston Scientific considering sale of snake venom unit

Go deeper